Goodpasture syndrome: Difference between revisions

(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Goodpasture syndrome (60%): diffuse pulmonary hemorrhage + acute glomerulonephritis.
*Goodpasture syndrome (60%): [[diffuse alveolar hemorrhage]] + acute [[glomerulonephritis]]
*Goodpasture disease: glomerulonephritis alone (30%,) pulmonary symptoms alone (10%,)  
*Goodpasture disease: [[glomerulonephritis]] alone (30%,) pulmonary symptoms alone (10%,)  
*Anti-GBM disease is most precise term for both entities.
*Anti-GBM disease is most precise term for both entities
**Type II hypersensitivty causing linear IG deposition in glomerular and alveolar BM.
**Type II hypersensitivity causing linear IG deposition in glomerular and alveolar BM
**Triggered by:Sepsis, URI, inhalation injury, smoking, pulmonary edema.
**Triggered by:
***[[Sepsis]]
***[[URI]]
***[[Inhalation injury]]
***Smoking
***[[Pulmonary edema]]


==Clinical Features==
==Clinical Features==
*Constitutional symptoms prior to pulmonary/renal complications
*Constitutional symptoms prior to pulmonary/renal complications
*Pulmonary
*Pulmonary
**Cough, dyspnea, chest pain, hemoptysis, respiratory failure or pulmonary hemorrhage
**[[Cough]], [[dyspnea]], [[chest pain]], [[hemoptysis]], [[respiratory failure]] or [[diffuse alveolar hemorrhage|pulmonary hemorrhage]]
*Renal
*Renal: [[glomerulonephritis]]
**See [[Glomerulonephritis]]
**[[Hematuria]], [[proteinuria]], RBC casts


==Differential Diagnosis==
==Differential Diagnosis==
Line 20: Line 25:
==Evaluation==
==Evaluation==
*Pulmonary
*Pulmonary
**Depends whether patient stable or not
**Depends whether patient stable or not, massive [[hemoptysis]] or not
**See [[hemoptysis]]
**Consider: [[CXR]] vs CT chest w/contrast, CBC, coags, T&S, bronchoscopy
*Renal:  
*Renal:  
*[[Urinalysis]], CBC, Chemistry, Albumin (often reduced in acute glomerulonephritis,) C3, C4, ASO, ANCA
**[[Urinalysis]], CBC, Chemistry, Albumin (often reduced in acute glomerulonephritis,) C3, C4, ASO, ANCA


==Management==
==Management==
*See [[Hemoptysis]]
*See [[Hemoptysis]]
*See [[Glomerulonephritis]]
**Massive: intubate (ideally ETT >8.0), angio or bronch to identify and stop localized source, consider nebulized [[TXA]]
**Correct [[coagulopathy]]
**[[Methylprednisolone]] 1g + [[plasmapheresis]]
*See [[Glomerulonephritis]], consult nephrology
*[[Plasmapheresis]] shown to be beneficial <ref> Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001 Jun 5. 134(11):1033-42 </ref>
*[[Plasmapheresis]] shown to be beneficial <ref> Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001 Jun 5. 134(11):1033-42 </ref>
*In severe cases may need:
*In severe cases may need:

Revision as of 16:02, 12 October 2019

Background

Clinical Features

Differential Diagnosis

Hemoptysis

Causes of Glomerulonephritis

Evaluation

  • Pulmonary
    • Depends whether patient stable or not, massive hemoptysis or not
    • Consider: CXR vs CT chest w/contrast, CBC, coags, T&S, bronchoscopy
  • Renal:
    • Urinalysis, CBC, Chemistry, Albumin (often reduced in acute glomerulonephritis,) C3, C4, ASO, ANCA

Management

Disposition

Admit for:

  • Decompensated disease
  • Massive hemoptysis
  • Acute glomerulonephritis

See Also

External Links

References

  • Chan AL, Louie S, Leslie KO, Juarez MM, Albertson TE. Cutting edge issues in Goodpasture's disease. Clin Rev Allergy Immunol. 2011 Oct. 41(2):151-62.
  • Kathuria, P; Sanghera, P; Stevenson, FT; Sharma, S; Lederer, E; Lohr, JW; Talavera, F; Verrelli, M (21 May 2013). Batuman, C, ed. "Goodpasture Syndrome". Medscape Reference. WebMD. Retrieved 23 Jan 2016
  1. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001 Jun 5. 134(11):1033-42